CTLA4 and neoplasm: Immune checkpoint inhibitors targeting these molecules, notably cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-1 (PD-1), and its ligand programmed death-ligand 1 (PD-L1), have been developed to block the tumor-induced immunomodulation.